



Published in final edited form as:

*Clin Cancer Res.* 2019 April 01; 25(7): 2194–2205. doi:10.1158/1078-0432.CCR-18-1955.

## Single Cell Transcriptomics of Pancreatic Cancer Precursors Demonstrates Epithelial and Microenvironmental Heterogeneity as an Early Event in Neoplastic Progression

Vincent Bernard<sup>1,2,3,\*</sup>, Alexander Semaan<sup>1,3,\*</sup>, Jonathan Huang<sup>1,3,\*</sup>, F. Anthony San Lucas<sup>4,\*</sup>, Feven C Mulu<sup>1,3</sup>, Bret M Stephens<sup>1,3</sup>, Paola A. Guerrero<sup>1,3</sup>, Yanqing Huang<sup>5</sup>, Jun Zhao<sup>1,3</sup>, Nabiollah Kamyabi<sup>1,3</sup>, Subrata Sen<sup>1</sup>, Paul A Scheet<sup>4</sup>, Cullen M Taniguchi<sup>5</sup>, Michael P Kim<sup>6</sup>, Ching-Wei Tzeng<sup>6</sup>, Matthew H Katz<sup>6</sup>, Aatur D Singhi<sup>7</sup>, Anirban Maitra<sup>1,3</sup>, and Hector A Alvarez<sup>8,#</sup>

<sup>1</sup>Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA

<sup>2</sup>The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Houston, TX 77030

<sup>3</sup>Sheikh Ahmed Pancreatic Cancer Research Center, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA

<sup>4</sup>Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA

<sup>5</sup>Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA

<sup>6</sup>Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA

<sup>7</sup>Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA, 15213, USA

<sup>8</sup>Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA

### Abstract

**Purpose:** Early detection of pancreatic ductal adenocarcinoma (PDAC) remains elusive. Precursor lesions of PDAC, specifically, intraductal papillary mucinous neoplasms (IPMNs) represent a *bona fide* pathway to invasive neoplasia, although the molecular correlates of progression remain to be fully elucidated. Single cell transcriptomics provides a unique avenue for dissecting both the epithelial and microenvironmental heterogeneity that accompany multistep progression from non-invasive IPMNs to PDAC.

#Corresponding author: Hector A Alvarez, MD, Ph.D., Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA, HAAAlvarez@mdanderson.org.

\*These authors contributed equally

Conflict of interest: None

**Methods:** Single cell RNA-sequencing was performed through droplet-based sequencing on 5,403 cells from two low-grade IPMNs (LGD-IPMN), two high-grade IPMNs (HGD-IPMN), and two PDACs (all surgically resected).

**Results:** Analysis of single cell transcriptomes revealed heterogeneous alterations within the epithelium and the tumor microenvironment during the progression of non-invasive dysplasia to invasive cancer. While HGD-IPMNs expressed many core-signaling pathways described in PDAC, LGD-IPMNs harbored subsets of single cells with a transcriptomic profile that overlapped with invasive cancer. Notably, a pro-inflammatory immune component was readily seen in low-grade IPMNs, comprised of cytotoxic T-cells, activated T-helper cells, and dendritic cells, which was progressively depleted during neoplastic progression, accompanied by infiltration of myeloid-derived suppressor cells. Finally, stromal myofibroblast populations were heterogeneous, and acquired a previously described tumor-promoting and immune-evading phenotype during invasive carcinogenesis.

**Conclusions:** This study demonstrates the ability to perform high resolution profiling of the transcriptomic changes that occur during multistep progression of cystic PDAC precursors to cancer. Notably, single cell analysis provides an unparalleled insight into both the epithelial and microenvironmental heterogeneity that accompany early cancer pathogenesis, and might be a useful substrate to identify targets for cancer interception.

### Keywords

single-cell RNA sequencing; pancreatic cancer; intraductal papillary mucinous neoplasm; transcriptomic heterogeneity; precancer atlas

### Introduction

Pancreatic ductal adenocarcinoma (PDAC) is the 3rd leading cause of cancer-related deaths in the United States, and most patients present with unresectable disease due to the lack of effective early detection strategies (1). This reiterates the critical need for understanding the pathogenesis of early neoplasia with the goal of developing biomarkers and molecular targets for cancer interception. The most common cystic neoplasm that is a *bona fide* precursor to PDAC is Intraductal Papillary Mucinous Neoplasms (IPMNs), which comprise roughly 40–50% of resected lesions that are initially diagnosed as asymptomatic pancreatic cysts (2). While most IPMNs harbor low-grade dysplasia (LGD), it is imperative to distinguish IPMNs that have progressed to high-grade dysplasia (HGD), or harbor an outright invasive component (PDAC). To guide clinicians with identifying IPMNs harboring HGD or PDAC, several radiological “high risk” or “worrisome features” (so-called Sendai and Fukuoka criteria) have been proposed (3). Although the rate of overdiagnosis and over-treatment have been significantly reduced, these criteria still lack optimal sensitivity and specificity (4). While patients with non-invasive IPMNs have an excellent prognosis upon surgical resection, once an IPMN develops an invasive component, the probability of long-term survival drops significantly (5). Although we have now elucidated the signature driver mutations (*KRAS* and *GNAS*) that distinguish IPMNs from other pancreatic cysts, these do not reliably distinguish between indolent *versus* aggressive IPMNs (6,7). In fact, the overall state of knowledge remains rudimentary, especially with regards to molecular metrics that

can identify ‘aggressive’ precancerous lesions that are likely to progress to carcinoma and require intervention from those that are ‘indolent’ and will naturally regress or remain stable. Thus, much remains to be elucidated in terms of biomarkers of IPMN progression and the underlying molecular features of dysplastic cells that predicate to invasive neoplasia.

The application of single cell DNA and RNA sequencing to cancers has provided unprecedented insights into tumor and microenvironmental heterogeneity present in established cancers. However, the extrapolation of these technologies to the compendium of precursor lesions has been scarce. In the specific context of the pancreas, prior studies have established the transcriptional profiles of normal cell types, such as islet cells, using single cell approaches (8–10). In this study, we perform the first reported single cell transcriptomic profiling of cystic precursor lesions of PDAC spanning histological grades of dysplastic epithelium. Specifically, we demonstrate our ability to generate transcriptomic libraries from >5400 single cells from surgically resected pancreatic tissues, including two IPMN with LGD, two IPMNs with HGD, and two PDAC lesions utilizing a droplet-based single-cell RNA-seq methodology(11). Our results demonstrate that epithelial and stromal heterogeneity is evident even within precursor lesions during multistep carcinogenesis, and reflect the progressive co-option of the microenvironment towards a tumor-promoting milieu.

## Materials and methods

### Cell line and fresh tissue material from surgically resected IPMNs and PDAC

A total of six patients were recruited at MD Anderson Cancer Center (MDACC) and University of Pittsburgh Medical Center (UPMC) through informed written consent following institutional review board (IRB) approval at both institutions (PA15–0014, Lab08–0098, Lab05–0080, Lab00–396). This study was conducted in accordance to Good Clinical Practices concerning medical research in humans per the Declaration of Helsinki. Two PDACs and one HGD-IPMN was profiled from MDACC and two LGD-IPMNs and one HGD-IPMN was profiled from UPMC. A previously established pancreatic tumoroid line (MP81) was also profiled (12). Tumoroid line source was validated through STR DNA fingerprinting and confirmed to be mycoplasma-free. Histological subtypes of IPMN included in this study were gastric (one LGD-IPMN), intestinal (one LGD-IPMN), and pancreatobiliary (two HGD-IPMN). Tumor cellularity was determined by pathologic review of tissue and compared to yield of cell phenotypes from single cell RNA-seq.

### Preparation of fresh tissue material and dissociation into single cell

Pancreatic tissue was delivered to the laboratory on ice after surgical resection in DMEM, high glucose, GlutaMAX™ Supplement, HEPES (Thermo fisher, 10564011) in 1% Bovine Serum Albumin (Thermo fisher, B14) in a 15ml conical tube. Tissue was then transferred to a 35×12mm Petri Dish(Thermo fisher, #150318), and minced with sterile surgical scalpel to 0.5–1.0mm fragments in approximately 1ml of the media.

Tissue digestion was performed with Liberase™ TH Research Grade (Sigma-Aldrich, 5401135001) alone for IPMN samples, or with both Liberase™ TH Research Grade and

Accutase® solution for PDAC tissues (Sigma-Aldrich, A6964). For warm digestion with Liberase™ TH Research Grade, pancreatic tissue fragments were incubated to a final concentration of 10 mg/ml, and placed on an incubated orbital shaker at 37 °C, 225 RPM for 20 min and gently pipetted every 10 min. At the end of the digestion period, the fragments (tissue slurry) were gently pipetted and washed to maximize the release of single cells. The tissue slurry was passed through a 100µm cell strainer followed by a 35µm cell strainer. The single-cell suspension was transferred to a new 15ml conical tube and centrifuged for 5 min at 400 RCF at 4°C. The supernatant was discarded and the cell pellet was re-suspended in 400 µl of PBS for downstream cell viability analysis and cell counting.

For warm digestion of PDAC tissues, we followed the identical procedure above as the IPMNs, followed by a second digestion period using sterile-filtered Accutase® solution, and placed on a shaker at 37 °C, 225 RPM for 30min, with gentle pipetting every 10 minutes.

### ddSEQ Surecell Library Preparation

Single cell transcriptomic amplification and library prep was performed using the SureCell WTA 3' Library Prep Kit for the ddSEQ System following the manufacturer's recommendations (Illumina, Cat# 20014279). Samples were processed across six sequential ddSEQ runs. Briefly, single cells were individually partitioned into sub-nanoliter droplets. Single cells were then lysed and barcoded inside individual droplets, with subsequent first strand synthesis. Individual droplets containing barcoded sample cells were disintegrated, purified, and subject to second strand cDNA synthesis. Purified amplified cDNA was subsequently quantified on a 2200 TapeStation System (Agilent) in order to validate quality of amplification by quantifying the area under the curve in regions between 200–5000 bp range on a D5000 high sensitivity screentape (Supplementary Figure 5A). Successful reactions (>2ng yield) were then fragmented and amplified using Nextera technology for low input cDNA material. Double sided size selection and library purification was performed utilizing purification beads per the manufacturer's protocol to remove short library fragments. Final library quality and concentration was measured by TapeStation (Supplementary Figure 5B) as the area under the curve. Libraries were sequenced on across six Illumina NextSeq 500 runs.

### Single cell clustering and transcriptomic analyses

Resulting FastQ files were run through the Single cell RNA-seq app on BaseSpace. Briefly, reads were aligned against a reference genome using Spliced Transcripts Alignment to a Reference (STAR), followed by barcode tagging and BAM indexing (13). Count files are generated using gene UMI counter and with cells passing quality filter based on cells above background and passing knee filter.

To perform the T-SNE clustering and additional downstream analysis the UMI count files were compiled into sparse matrices and subsequently filtered based on the criteria that each cell must express a minimum of 300 genes and be composed of less than 15% mitochondrial genes. Following filtering, the data is log normalized, scaled and centered. The output is then analyzed by principal component analysis (PCA). After identifying the number of dimensions to use, the result is clustered in a shared nearest neighbor algorithm and T-SNE

before plotting. The resulting T-SNE plots were colored according to specific features to visually present expression of genes in various clusters. These annotated matrices were also used to find differentially expressed genes between subpopulations. Heatmaps organized by annotated clusters were generated by plotting the top 20 differentially expressed genes associating with each cluster. Functions for analysis were provided through the recommended workflow in the Seurat package (11).

The correlation matrices were created based on the filtered list of cells used in the T-SNE. Matrices were formed through the function 'cor' from the stats package. The Pearson correlation coefficients were then plotted in ComplexHeatmap(14). Cells are ordered through hierarchical clustering. For cell cycle analysis, we defined a cell cycle characteristic coefficient as the average of the  $\log_2(\text{TPM} + 1)$  across genes for a cell from the gene ontology set (version 6.2 MSigDB) related to G1, S, G2, and M phases respectively (15,16). These coefficients were then plotted in ComplexHeatmap (13) and hierarchically clustered by cell. All T-SNE and heatmaps were run in R v3.4.2.

## Results

### Concordance of single cell RNA sequencing to bulk cell lines

Prior to tissue profiling, we investigated the concordance of bulk and single cell RNA sequencing profiles from a PDAC tumoroid line (MP81) using the droplet-based sequencing technology. Single cell and bulk cell RNA libraries were made using Nextera library preparation chemistry. Single cell RNA-seq was performed at 670 million reads, resulting in 30.4% of the reads mapping to the coding sequence (CDS) regions, and 37.7% mapping to UTR regions with 91,032 reads, 10,800 unique molecular identifier (UMI) counts, and a median of 3,293 unique genes detected per cell passing filter. Correlations in gene expression levels between 2,022 single cells, and bulk cell suspension was excellent ( $r_s > 0.9$ ), with total coverage gene counts of 17,507 and 15,185 for single cells and bulk cells respectively (Supplementary Figure 1A). We also verified the concordance of gene counts across two independent replicates of single cell library preparation from the same cell line sample. This revealed a high correlation in gene expression levels ( $r_s > 0.9$ ) with almost identical levels of gene coverage (14,994 and 14,488) (Supplementary Figure 1B).

### Preneoplastic epithelium of IPMNs demonstrates both unique and shared transcriptomic signatures with PDAC

We subsequently applied droplet-based single cell RNA sequencing to study the diverse transcriptional profiles that exist within surgically resected preneoplastic (IPMNs) and invasive (PDAC) pancreatic lesions (Supplementary Figures 1C-D, 2 and Supplementary Table 1). Cumulatively amongst all of the tissue samples, 5,403 single cells were sequenced. Cells with low expression of genes (<300 genes) and high percentage of mitochondrial genes expressed (>10%) were digitally filtered out resulting in, 3,343 single cells used for the subsequent analysis. Scatter plots of number of UMIs compared to number of genes and abundance of mitochondrial transcripts revealed consistent read depth across single cells between lesions and absence of apoptosis induced transcript batch effects (Supplementary Figure 1C). The mean number of genes and UMIs detected per cell was 1101 and 3194

respectively. After identifying the top variable genes, we performed principal component analysis (PCA) and determined which principal components (Supplementary Figure 1D) to use for unsupervised clustering using t-distribution stochastic neighbor embedding (t-SNE) (17) which was implemented using the SEURAT package (Figure 1A) (11). This analysis identified ten distinct subpopulations (“clusters”) comprised of unique stromal and epithelial components classified defined by characteristic gene expression patterns (Figure 1B-C, Supplementary Table 2, Supplementary Figure 3).

We first identified the neoplastic single cell “clusters” through previously defined signature transcripts for pancreatic epithelial lesions, including *KRT19* and *MUC1*, which were present among all samples types (IPMNs and PDAC) irrespective of grade if dysplasia or invasion(18,19) (Figure 2A). We subsequently sought to correlate the histological grading of the designated “clusters” with known biomarkers of dysplastic progression to cancer. This revealed high expression of transcripts like *CEACAM6* within subpopulations of HGD-IPMN and PDAC samples, which confirmed previously published data on this marker in bulk RNA analysis and immunohistochemistry of intact tissues (20,21). Conversely, we observed high expression of *MUC5AC*, which encodes for an apomucin mostly seen in LGD and downregulated during histological progression, within the LGD-IPMNs compared to the other sample types (18).

In an effort to identify “cluster-defining” signatures, we profiled the top 25 differentially expressed genes within each of the ten distinct single cell “cluster” (Figure 2B, Supplementary Table 3). Annotation of the resulting transcripts revealed aberrant expression of multiple cancer-related genes even within the LGD-IPMN cells designated as “clusters” LG.Ep1, 2, and 3 (Figure 1B). These include overexpression of transcripts such as *TFF3* and *REG4* that have been previously described as upregulated during cancer progression(22,23). On the contrary, the LGD-IPMN clusters demonstrated persistent expression of putative tumor suppressor genes (TSGs) such as *RAP1GAP* that have been shown to suppress tumor invasion and metastases across various cancers (including RAS mutant neoplasms) (24), while HGD-IPMNs (HG.Ep) revealed downregulation of the aforementioned TSGs, concomitant with higher expression of oncogenic transcripts previously associated with progression to PDAC such as *S100P* and *S100A10*, amongst others (25–27).

We then investigated whether biological differences could be observed through gene ontology and pathway analyses (IPA: Ingenuity Pathways Analysis) of differentially expressed genes between neoplastic epithelial clusters (Figure 1B). Several aberrant canonical pathways were identified during the transition from LGD to HGD IPMN that are related to previously published core signaling pathways in PDAC, including integrin signaling, signaling by small GTPases, Wnt/B-catenin signaling, axonal guidance signaling, apoptosis, and G1/S phase regulation (Supplementary Table 4) (28,29). When comparing the PDAC and LGD lesions, aberrant expression of the same pathways was observed, with the additional deregulation of DNA damage response, TGF-B signaling, and SAPK/JNK signaling. Other aberrant canonical pathways identified during transition from LGD to HGD and PDAC lesions include metabolism related pathways such as oxidative phosphorylation and mitochondrial dysfunction, as well as mTOR signaling (Supplementary Table 5).

Cell cycle analysis of epithelial cells across lesion types revealed higher proliferative states (G2/M and S phase) in cells derived from PDAC compared to LGD and HGD lesions (Figure 1D). Generally, there was a significant proportion of LGD cells with low expression of cell cycle genes likely representing cells within low proliferative states (G0 phase). On the other hand, there is a small population of cells derived from LGD lesions (LG.Ep3) with high expression of proliferation related genes, which may represent a more aggressive subpopulation within this lesional type. This may suggest that even within lesions histologically identified as low grade, there exist rare populations of cells with varying degrees of putative malignant potential. Further, it is important to note that even “adenocarcinoma”-designated clusters contained cells originating from LGD-IPMNs with associated expression of PDAC core signaling pathways and deregulation of tumor suppressor genes (Figure 2C). In our particular data set, 1.2% of epithelial cells from LGD-IPMNs were found in adenocarcinoma related clusters. Additionally, up to 8.9% of cells from LGD-IPMNs tended to cluster with HGD-IPMNs with their respective changes in gene expression pathways. This suggests that even within IPMNs with otherwise LGD histology, there are cells that phenocopy the transcriptomic features of invasive neoplasia (Supplementary Figure 2). The expression profiles of such low frequency cells within LGD-IPMNs would likely be missed during bulk RNA sequencing, and further underscores the utility of the single cell sequencing approach in elucidating the epithelial heterogeneity that exists even within early precursor lesions of PDAC.

Analysis of the cell-to-cell correlations for gene expression of the 3,343 cells demonstrated relatively higher intra-tumoral coherence among cells from LGD and HGD lesions compared with those from PDAC (Figure 2D), a not surprising finding suggesting an increase in intra-tumoral epithelial heterogeneity during the progression from IPMNs to PDAC (30). Inter-lesion correlation was better observed in cells derived from stromal components including myeloid and lymphocytic populations, whereby a significant number of populations showed similarities across tissue types (Figure 1A-C). This suggests the presence of common cancer associated immune components among lesion types. On the other hand, even though these stromal components tended to cluster with one another (Figure 1B), correlation heat maps suggested the presence of multiple unique subtypes within the stroma and non-random variations during histological progression to cancer (Supplementary Figure 4, *and results below*).

### **Virtual microdissection of stromal and immune heterogeneity during IPMN progression**

In an effort to better identify unique subpopulations of stromal components across lesion types, we opted to perform single cell digital microdissection of only stromal cells and exclude epithelial components. This resulted in the identification of seven unique clusters with varying degrees of enrichment across lesions types (Figures 3a,b). Differential expression of the top 20 genes across clusters allowed us to identify distinct immune and myofibroblast-derived phenotypes within each lesional subtype (Figure 3c,d).

A high proportion of cytotoxic T cells (measured by CD8, and presence of granzyme and perforin related transcripts) were observed in LGD-IPMNs compared to HGD-IPMNs and PDAC. In proportion to other immune subtypes, CD4 T cells also appear to be more highly

enriched in LGD-IPMN compared to others, and present with generalized activation as defined by expression of *CD69*. We also detected the presence of rare B-cell populations (expressing CD20 and CD19) that are present in both HGD-IPMNs and in LGD-IPMNs, but are completely absent in PDACs. Presence of tumor infiltrating B-cells have recently been described in PanIN lesions with an immunosuppressive role during the initiating stages of PDAC multistep progression, and may, in fact, have a similar role in the context of IPMNs based on these findings (10,31,32).

Notably, we observed a significantly enriched proportion of myeloid derived suppressor cells (MDSCs), within the stromal component of PDAC, representing 51% (277/544) of single stromal cells profiled, compared to 2.3% (3/131) and 3.5% (10/281) within LGD-IPMNs and HGD-IPMNs respectively. These MDSCs resemble the pro-tumorigenic polymorphonuclear myeloid-derived suppressor cell (PMN-MDSC) phenotype based on expression of CD11b (*ITGAM*), S100A9, CCL3, and APOE, which has been previously described to be prevalent during cancer progression (33). Among myeloid derived populations, we also observed cDC2 type dendritic cells, characterized by expression of CD1C, THBD, and *FCERIA* (34). These cells have been shown to have T-cell stimulatory potential and are critical mediators of cross presentation of tumor antigens mediated through the high-affinity IgE receptor FcεRI (*FCERIA*) (35). This pro-inflammatory subpopulation appears in greater proportions amongst LGD and HGD-IPMNs, suggesting a more prevalent predication for anti-tumor immune response within pre-neoplastic lesions.

Heterogeneous fibroblast populations across histological subtypes were also identified potentially representing distinct stromal functions during tumorigenesis. For example, the fibroblast subtype known as “inflammatory” CAF (iCAF) is characterized by expression of *VIM*, *FAP*, *COL3A1*, *DES*, *IL6*, and *CXCL12* and reduced expression of α-SMA (*ACTA2*) (36,37). This subpopulation has been shown to be involved in immunosuppression, growth factor secretion, and promotion of pro-tumorigenic mechanisms facilitating invasion and metastasis(36), which might correlate with its exclusive representation in PDAC derived clusters, representing 10.5% (58/544) of single stromal cells profiled, and absence within non-invasive IPMNs. A separate compartment of CAFs, described as myofibroblasts (“myCAFs”), with increased alpha-SMA expression and reduced expression of *CXCL12* and *DES*, was also identified. These myCAFs have been implicated in distinct functions from iCAFs, including secretion of autocrine stromal and endothelial growth factors (36). This population is rare in LGD-IPMNs, but is highly represented in HGD-IPMNs suggesting that activation of fibroblasts to the myCAF phenotype tends to occur even within non-invasive dysplastic lesions (Figure 4).

## Discussion

Histologically well-established precancerous lesions precede the onset of PDAC by years, if not decades. With an increasing use of diagnostic cross-sectional imaging, incidence of precancerous lesions in the form of pancreatic cysts is rising even in clinically healthy individuals (38–40). In general, approximately 2.4 % of the general population undergoing MRI present with a cystic pancreatic lesion with individuals over 70 years having an incidence of up to 10% (41). To guide clinicians, several radiologic guidelines have been



reported and progressively updated (3,42,43). In general, large, symptomatic main duct IPMNs with enhancing mural nodules show the highest probability of malignant transformation; frequency of invasive IPMN is 43.1% (range, 11–81%) and should be surgically treated (3). Yet several other case series of resected IPMNs report a wide range of IPMN-related pancreatic adenocarcinoma (6% - 81%) (44–46). A balance between diagnosis of potentially invasive IPMNs and harmful overtreatment of patients is thus crucial in our approach stratification of cystic lesions. In the current study, we describe an approach at profiling the molecular events that occur during pancreatic carcinogenesis in the context of these cystic precursors (IPMNs) with the goal of understanding the heterogeneity of epithelial and stromal components that might delineate lesions with an aggressive potential. We do this through high-resolution single cell RNA sequencing of LGD-IPMN, HGD-IPMN, and PDACs, which allows us to specifically profile aberrant pathways across multiple cell types. Interestingly, progression from LGD and HGD lesions to invasive PDAC revealed shifts in distinct cell populations encompassing both epithelial and stromal/immune compartments.

Among epithelial populations, we detected expression of transcripts of gastric lineage that have been previously described during IPMN progression and have been correlated with better prognosis, such as *MUC5AC*, as differentially overexpressed in our LGD lesions (47). Although oncogenic transcripts are also expressed at the LGD stage, there appears to be retained expression of tumor suppressor related pathways which may help counteract further dysplastic progression of these lesions. Within HGD lesions, differential expression of these tumor suppressor pathways are no longer detected and we begin to find previously described classical core signaling pathways in PDAC (29,48).

As a stroma-rich cancer, multiple studies have shown how the diverse tumor microenvironment (TME) plays a crucial role in the development, progression, and immune evasion that exemplifies the biology of PDAC (49,50). As previously shown by Moffit et al., “virtual microdissection” of stromal genes revealed an “activated” subpopulation of stroma characterized by overexpression of inflammatory pathways (51). Although these findings are further validated within our own study, Moffit et al., were not able to distinguish specific contributions of immune and myofibroblast components to this signature. By dissecting specific cell-types at the single cell level, we further delineate this signature to describe the dichotomy of “myCAF” versus “iCAF” fibroblast populations during multistep progression, with the former cells observed (albeit rarely) even in LGD-IPMNs and the latter cells only identified in PDAC samples. Within our analysis, besides expression of many typical CAF markers (*FAP*, *THY1*, and *DES*), the iCAF cells also show a unique expression pattern of the C-X-C motif chemokine ligand 12 (CXCL12) (52). This chemokine and its corresponding receptor (CXCR4) are believed to play a crucial role in many solid cancers, and are associated with metastatic spread in breast cancer, lung cancer and melanoma (53–56). Accumulating evidence also points to a role in PDAC progression, with higher expression of CXCL12 correlating with metastasis, likely by facilitating immune evasion, and increased levels of matrix metalloproteinases leading to cellular invasion (57–60). Within our own study, we find similar trends in the presence of other cellular populations that parallel the emergence of CXCL12-expressing iCAFs, such as a decrease in cytotoxic T cell and

increase in myeloid suppressive proportions, creating the notorious immune suppressive TME well described in PDAC.

Myeloid derived subpopulations also tend to evolve during tumor progression. Comprised of multiple clusters expressing CD11b, ITGB2, CD13, CD18, and S100A9, a clear separation based on their individual transcriptomes remains difficult. This high overlap of myeloid derived subpopulations mirrors recent findings in breast cancer where previously proposed M1 and M2 macrophage associated genes are frequently expressed within the same cells among these two clusters (61). As Azizi et al, describes, this suggests that distinct prototypical macrophages may not be prevalent within tumors and may in fact exist within the spectrum of these two phenotypes. Among other myeloid derived populations, we do identify PMN-MDSCs which are known surrogates of prognosis and contribute to immune evasion and tumor progression through neo-angiogenesis, migration and invasion, and thus metastatic spread (62,63). Similar to the elevated proportion of CAFs experienced in more advanced disease we describe a striking increase in MDSC populations compared to pre-neoplastic lesions (51% of non-epithelial cell types in PDAC, versus <5% in non-invasive IPMNs). This resembles findings from Kumar et al. whereby CAFs are able to actively recruit PMN-MDSC to tumors, further supporting the role of an “inflammatory CAF” subpopulation in promoting immunosuppression (64). Additional work has described the importance of immune populations during tumorigenesis in the context of IPMNs specifically (65). Spatial characteristics as related to epithelial and cytotoxic T cell, as well as myeloid cell and cytotoxic T cell proximity has been shown to be a predictive feature of the presence of high grade dysplasia. This is believed to be caused by immunosuppressive interactions derived from tumor cells and myeloid cells against cytotoxic T cells, regulating tumor development. With further data supporting the role of myeloid derived cytotoxic T cell suppression, immunotherapeutic approaches targeting this crosstalk may serve as a novel strategy at impeding tumor progression (10,66).

The identification of demonstrable dendritic cell (DC) populations within LGD and HGD IPMN microenvironment suggests a pro-inflammatory phase that is present during the non-invasive precursor states. This is particularly true in LGD IPMNs where a higher proportion of cytotoxic T cells exist in comparison to other lesion types that may be supported by cDC2 cells through cross presentation of tumor antigens and T-cell stimulation. Additionally, the presence of these dendritic cells in IPMNs may also provide opportunities for cancer “immune interception”, since dendritic cell targeted vaccines have previously shown effectiveness in the context of an myeloid immunosuppressive environment through reduction of PMN-MDSCs (67).

Although single cell RNA sequencing provides new tools for high resolution profiling of cell populations, it is not without its limitations, particularly in the context of this study. While these methodologies are accurate in determining relative abundance of transcripts, they suffer when attempting to capture lowly expressed genes (68). This is mostly of symptom of droplet-based approaches as currently described. While they allow for high throughput sequencing of thousands of single cells from a single sample by counting the 3' end of transcripts, sensitive detection of low to moderately expressed mRNA transcripts is forfeited compared to those methodologies providing full length transcript data (68–70). Within this

study, as we aimed to profile the complex heterogeneity of these preneoplastic tissues, and thus maximizing throughput through a droplet-based approach was prioritized yet at the cost of observing an average of 1101 genes per cell. Sequencing depth is another important consideration, as low read depth would not be optimal for providing detailed transcript information from a single cell which may contain subtle changes gene expression signatures. But even with increasing sequencing depth, transcript dropout remains a significant limitation where poor mRNA capture and amplification may result in up to 72% of loss transcripts, particularly in genes expressed at low levels (68). It is also important to note that single cell dissociation of tissues remains a challenging protocol, for one thing to maintain viability of cells throughout the process, and the other to maintain relative cell representation as isolation protocols often lead to selective degradation of specific cell types. There also remains the potential for these methodologies to alter expression states and mRNA levels during this process. Further work has demonstrated that this can be ameliorated through RNA-seq of single nuclei which may result in less of a bias of cell populations (19,71). Further limitations within our own study include the low number of samples profiled. This is mostly a consequence of the relative paucity of freshly resected surgical samples from pancreatic cysts of appropriate cellularity (low grade cysts are particularly challenging in being paucicellular), as well as the difficulty of obtaining adequate viability following single cell dissociation in order to create viable cDNA and sequencing libraries. This further exacerbates the fact we could not obtain consistent histological subtypes in our preneoplastic lesions which can have a direct impact on transcriptomic heterogeneity.

In conclusion, we describe how the TME may evolve during the multistep progression of IPMNs to PDAC, whereby the non-invasive precursor lesions begin to experience a loss of cytotoxic T-cells during dysplastic progression and begin to assimilate immune components such as PMN-MDSCs, with immune suppressive properties. Additionally, we demonstrate this permissive microenvironment is correlated with appearance of tumor-promoting iCAF stromal cell populations that facilitate immune evasion. Notably, single cell analysis of IPMNs reveals, for the first time, that even in otherwise histologically innocuous LGD-IPMNs, we find minor populations of cells that transcriptionally phenocopy HGD and PDAC (~9% and ~1% of LGD-IPMN cells, respectively). It is possible that future single cell analyses on a larger series of LGD-IPMNs might establish a “threshold” which portends aggressive natural history even in the absence of radiologically detectable worrisome features. Although it is important to stress the limited generalizations that can be made from such a small subset of lesions, the ability to detect these gene expression patterns among single cells provides a primer for uncovering how heterogeneous cell types contribute to tumor carcinogenesis. Leveraging this strategy may thus facilitate elucidation of molecular biomarkers for disease stratification.

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## Acknowledgments

This work was supported by the MD Anderson Moonshot Program and the Khalifa Bin Zayed Al-Nahyan Foundation; the National Institute of Health (U01CA196403 and U01CA200468 to AM); the Cancer Prevention

Research Institute of Texas (RP170067 to VB and NK), the DFG (German Research Foundation) (SE-2616/2-1 to A.S).

## References

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. *CA Cancer J Clin* 2018 doi 10.3322/caac.21442.
2. Salvia R, Crippa S, Partelli S, Armatura G, Malleo G, Paini M, et al. Differences between main-duct and branch-duct intraductal papillary mucinous neoplasms of the pancreas. *World J Gastrointest Surg* 2010;2(10):342–6 doi 10.4240/wjgs.v2.i10.342. [PubMed: 21160841]
3. Tanaka M, Fernandez-Del Castillo C, Kamisawa T, Jang JY, Levy P, Ohtsuka T, et al. Revisions of international consensus Fukuoka guidelines for the management of IPMN of the pancreas. *Pancreatology* 2017;17(5):738–53 doi 10.1016/j.pan.2017.07.007. [PubMed: 28735806]
4. Heckler M, Michalski CW, Schaeffle S, Kaiser J, Buchler MW, Hackert T. The Sendai and Fukuoka consensus criteria for the management of branch duct IPMN - A meta-analysis on their accuracy. *Pancreatology* 2017;17(2):255–62 doi 10.1016/j.pan.2017.01.011. [PubMed: 28189431]
5. Rezaee N, Barbon C, Zaki A, He J, Salman B, Hruban RH, et al. Intraductal papillary mucinous neoplasm (IPMN) with high-grade dysplasia is a risk factor for the subsequent development of pancreatic ductal adenocarcinoma. *HPB (Oxford)* 2016;18(3):236–46 doi 10.1016/j.hpb.2015.10.010. [PubMed: 27017163]
6. Molin MD, Matthaei H, Wu J, Blackford A, Debeljak M, Rezaee N, et al. Clinicopathological correlates of activating GNAS mutations in intraductal papillary mucinous neoplasm (IPMN) of the pancreas. *Ann Surg Oncol* 2013;20(12):3802–8 doi 10.1245/s10434-013-3096-1. [PubMed: 23846778]
7. Matthaei H, Wu J, Dal Molin M, Shi C, Perner S, Kristiansen G, et al. GNAS sequencing identifies IPMN-specific mutations in a subgroup of diminutive pancreatic cysts referred to as “incipient IPMNs”. *Am J Surg Pathol* 2014;38(3):360–3 doi 10.1097/PAS.0000000000000117. [PubMed: 24525507]
8. Segerstolpe A, Palasantza A, Eliasson P, Andersson EM, Andreasson AC, Sun X, et al. Single-Cell Transcriptome Profiling of Human Pancreatic Islets in Health and Type 2 Diabetes. *Cell Metab* 2016;24(4):593–607 doi 10.1016/j.cmet.2016.08.020. [PubMed: 27667667]
9. Muraro MJ, Dharmadhikari G, Grun D, Groen N, Dielen T, Jansen E, et al. A Single-Cell Transcriptome Atlas of the Human Pancreas. *Cell Syst* 2016;3(4):385–94 e3 doi 10.1016/j.cels.2016.09.002. [PubMed: 27693023]
10. Gunderson AJ, Kaneda MM, Tsujikawa T, Nguyen AV, Affara NI, Ruffell B, et al. Bruton Tyrosine Kinase-Dependent Immune Cell Cross-talk Drives Pancreas Cancer. *Cancer Discov* 2016;6(3):270–85 doi 10.1158/2159-8290.CD-15-0827. [PubMed: 26715645]
11. Macosko EZ, Basu A, Satija R, Nemes J, Shekhar K, Goldman M, et al. Highly Parallel Genome-wide Expression Profiling of Individual Cells Using Nanoliter Droplets. *Cell* 2015;161(5):1202–14 doi 10.1016/j.cell.2015.05.002. [PubMed: 26000488]
12. Sakellariou-Thompson D, Forget MA, Creasy C, Bernard V, Zhao L, Kim YU, et al. 4-1BB Agonist Focuses CD8(+) Tumor-Infiltrating T-Cell Growth into a Distinct Repertoire Capable of Tumor Recognition in Pancreatic Cancer. *Clinical cancer research : an official journal of the American Association for Cancer Research* 2017;23(23):7263–75 doi 10.1158/1078-0432.CCR-17-0831. [PubMed: 28947567]
13. Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast universal RNA-seq aligner. *Bioinformatics* 2013;29(1):15–21 doi 10.1093/bioinformatics/bts635. [PubMed: 23104886]
14. Gu Z, Eils R, Schlesner M. Complex heatmaps reveal patterns and correlations in multidimensional genomic data. *Bioinformatics* 2016;32(18):2847–9 doi 10.1093/bioinformatics/btw313. [PubMed: 27207943]
15. Liberzon A, Birger C, Thorvaldsdottir H, Ghandi M, Mesirov JP, Tamayo P. The Molecular Signatures Database (MSigDB) hallmark gene set collection. *Cell Syst* 2015;1(6):417–25 doi 10.1016/j.cels.2015.12.004. [PubMed: 26771021]

16. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. *Proc Natl Acad Sci U S A* 2005;102(43):15545–50 doi 10.1073/pnas.0506580102. [PubMed: 16199517]
17. Waltman LvE NJ A smart local moving algorithm for large-scale modularity-based community detection. *Eur Phys* 2013;86, 471
18. Jonckheere N, Skrypek N, Van Seuning I. Mucins and pancreatic cancer. *Cancers (Basel)* 2010;2(4):1794–812 doi 10.3390/cancers2041794. [PubMed: 24281201]
19. Gao R, Kim C, Sei E, Foukakis T, Crosetto N, Chan LK, et al. Nanogrid single-nucleus RNA sequencing reveals phenotypic diversity in breast cancer. *Nat Commun* 2017;8(1):228 doi 10.1038/s41467-017-00244-w. [PubMed: 28794488]
20. Duxbury MS, Matros E, Clancy T, Bailey G, Doff M, Zinner MJ, et al. CEACAM6 is a novel biomarker in pancreatic adenocarcinoma and PanIN lesions. *Ann Surg* 2005;241(3):491–6. [PubMed: 15729073]
21. Duxbury MS, Ito H, Benoit E, Ashley SW, Whang EE. CEACAM6 is a determinant of pancreatic adenocarcinoma cellular invasiveness. *Br J Cancer* 2004;91(7):1384–90 doi 10.1038/sj.bjc.6602113. [PubMed: 15316565]
22. Terris B, Blaveri E, Crnogorac-Jurcevic T, Jones M, Missiaglia E, Ruzsniwski P, et al. Characterization of gene expression profiles in intraductal papillary-mucinous tumors of the pancreas. *Am J Pathol* 2002;160(5):1745–54 doi 10.1016/S0002-9440(10)61121-2. [PubMed: 12000726]
23. He XJ, Jiang XT, Ma YY, Xia YJ, Wang HJ, Guan TP, et al. REG4 contributes to the invasiveness of pancreatic cancer by upregulating MMP-7 and MMP-9. *Cancer Sci* 2012;103(12):2082–91 doi 10.1111/cas.12018. [PubMed: 22957785]
24. Zhang L, Chenwei L, Mahmood R, van Golen K, Greenson J, Li G, et al. Identification of a putative tumor suppressor gene Rap1GAP in pancreatic cancer. *Cancer Res* 2006;66(2):898–906 doi 10.1158/0008-5472.CAN-05-3025. [PubMed: 16424023]
25. Arumugam T, Simeone DM, Van Golen K, Logsdon CD. S100P promotes pancreatic cancer growth, survival, and invasion. *Clin Cancer Res* 2005;11(15):5356–64 doi 10.1158/1078-0432.CCR-05-0092. [PubMed: 16061848]
26. Kim GE, Bae HI, Park HU, Kuan SF, Crawley SC, Ho JJ, et al. Aberrant expression of MUC5AC and MUC6 gastric mucins and sialyl Tn antigen in intraepithelial neoplasms of the pancreas. *Gastroenterology* 2002;123(4):1052–60. [PubMed: 12360467]
27. Sitek B, Sipos B, Alkatout I, Poschmann G, Stephan C, Schulenburg T, et al. Analysis of the pancreatic tumor progression by a quantitative proteomic approach and immunohistochemical validation. *J Proteome Res* 2009;8(4):1647–56 doi 10.1021/pr800890j. [PubMed: 19714807]
28. Bailey P, Chang DK, Nones K, Johns AL, Patch AM, Gingras MC, et al. Genomic analyses identify molecular subtypes of pancreatic cancer. *Nature* 2016;531(7592):47–52 doi 10.1038/nature16965. [PubMed: 26909576]
29. Biankin AV, Waddell N, Kassahn KS, Gingras MC, Muthuswamy LB, Johns AL, et al. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. *Nature* 2012;491(7424):399–405 doi 10.1038/nature11547. [PubMed: 23103869]
30. Oldfield LE, Connor AA, Gallinger S. Molecular Events in the Natural History of Pancreatic Cancer. *Trends Cancer* 2017;3(5):336–46 doi 10.1016/j.trecan.2017.04.005. [PubMed: 28718411]
31. Pylayeva-Gupta Y, Das S, Handler JS, Hajdu CH, Coffre M, Koralov SB, et al. IL35-Producing B Cells Promote the Development of Pancreatic Neoplasia. *Cancer Discov* 2016;6(3):247–55 doi 10.1158/2159-8290.CD-15-0843. [PubMed: 26715643]
32. Lee KE, Spata M, Bayne LJ, Buza EL, Durham AC, Allman D, et al. Hif1a Deletion Reveals Pro-Neoplastic Function of B Cells in Pancreatic Neoplasia. *Cancer Discov* 2016;6(3):256–69 doi 10.1158/2159-8290.CD-15-0822. [PubMed: 26715642]
33. Ouzounova M, Lee E, Piranlioglu R, El Andaloussi A, Kolhe R, Demirci MF, et al. Monocytic and granulocytic myeloid derived suppressor cells differentially regulate spatiotemporal tumour plasticity during metastatic cascade. *Nat Commun* 2017;8:14979 doi 10.1038/ncomms14979. [PubMed: 28382931]

34. Villani AC, Satiya R, Reynolds G, Sarkizova S, Shekhar K, Fletcher J, et al. Single-cell RNA-seq reveals new types of human blood dendritic cells, monocytes, and progenitors. *Science* 2017;356(6335) doi 10.1126/science.aah4573.
35. Platzer B, Elpek KG, Cremasco V, Baker K, Stout MM, Schultz C, et al. IgE/FcεpsilonRI-Mediated Antigen Cross-Presentation by Dendritic Cells Enhances Anti-Tumor Immune Responses. *Cell Rep* 2015 doi 10.1016/j.celrep.2015.02.015.
36. Ohlund D, Handly-Santana A, Biffi G, Elyada E, Almeida AS, Ponz-Sarvise M, et al. Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer. *J Exp Med* 2017;214(3):579–96 doi 10.1084/jem.20162024. [PubMed: 28232471]
37. Avery D, Govindaraju P, Jacob M, Todd L, Monslow J, Pure E. Extracellular matrix directs phenotypic heterogeneity of activated fibroblasts. *Matrix Biol* 2017 doi 10.1016/j.matbio.2017.12.003.
38. Canto MI, Hruban RH, Fishman EK, Kamel IR, Schulick R, Zhang Z, et al. Frequent detection of pancreatic lesions in asymptomatic high-risk individuals. *Gastroenterology* 2012;142(4):796–804; quiz e14–5 doi 10.1053/j.gastro.2012.01.005. [PubMed: 22245846]
39. Nougaret S, Mannelli L, Pierredon MA, Schembri V, Guiu B. Cystic pancreatic lesions: From increased diagnosis rate to new dilemmas. *Diagn Interv Imaging* 2016;97(12):1275–85 doi 10.1016/j.diii.2016.08.017. [PubMed: 27840080]
40. Klibansky DA, Reid-Lombardo KM, Gordon SR, Gardner TB. The clinical relevance of the increasing incidence of intraductal papillary mucinous neoplasm. *Clin Gastroenterol Hepatol* 2012;10(5):555–8 doi 10.1016/j.cgh.2011.12.029. [PubMed: 22210438]
41. de Jong K, Nio CY, Hermans JJ, Dijkgraaf MG, Gouma DJ, van Eijck CH, et al. High prevalence of pancreatic cysts detected by screening magnetic resonance imaging examinations. *Clin Gastroenterol Hepatol* 2010;8(9):806–11 doi 10.1016/j.cgh.2010.05.017. [PubMed: 20621679]
42. Vege SS, Ziring B, Jain R, Moayyedi P, Clinical Guidelines C, American Gastroenterology A. American gastroenterological association institute guideline on the diagnosis and management of asymptomatic neoplastic pancreatic cysts. *Gastroenterology* 2015;148(4):819–22; quiz e12–3 doi 10.1053/j.gastro.2015.01.015. [PubMed: 25805375]
43. European Study Group on Cystic Tumours of the P. European evidence-based guidelines on pancreatic cystic neoplasms. *Gut* 2018;67(5):789–804 doi 10.1136/gutjnl-2018-316027. [PubMed: 29574408]
44. Lee SY, Lee KT, Lee JK, Jeon YH, Choi D, Lim JH, et al. Long-term follow up results of intraductal papillary mucinous tumors of pancreas. *J Gastroenterol Hepatol* 2005;20(9):1379–84 doi 10.1111/j.1440-1746.2005.04014.x. [PubMed: 16105124]
45. Nara S, Onaya H, Hiraoka N, Shimada K, Sano T, Sakamoto Y, et al. Preoperative evaluation of invasive and noninvasive intraductal papillary-mucinous neoplasms of the pancreas: clinical, radiological, and pathological analysis of 123 cases. *Pancreas* 2009;38(1):8–16 doi 10.1097/MPA.0b013e318181b90d. [PubMed: 18665010]
46. Sadakari Y, Ienaga J, Kobayashi K, Miyasaka Y, Takahata S, Nakamura M, et al. Cyst size indicates malignant transformation in branch duct intraductal papillary mucinous neoplasm of the pancreas without mural nodules. *Pancreas* 2010;39(2):232–6 doi 10.1097/MPA.0b013e318181bab60e. [PubMed: 19752768]
47. Yonezawa S, Horinouchi M, Osako M, Kubo M, Takao S, Arimura Y, et al. Gene expression of gastric type mucin (MUC5AC) in pancreatic tumors: its relationship with the biological behavior of the tumor. *Pathol Int* 1999;49(1):45–54. [PubMed: 10227724]
48. Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. *Science (New York, NY)* 2008;321(5897):1801–6 doi 10.1126/science.1164368.
49. Kalluri R The biology and function of fibroblasts in cancer. *Nature reviews Cancer* 2016;16(9):582–98 doi 10.1038/nrc.2016.73. [PubMed: 27550820]
50. Chang JH, Jiang Y, Pillarisetty VG. Role of immune cells in pancreatic cancer from bench to clinical application: An updated review. *Medicine (Baltimore)* 2016;95(49):e5541 doi 10.1097/MD.0000000000005541. [PubMed: 27930550]


51. Moffitt RA, Marayati R, Flate EL, Volmar KE, Loeza SG, Hoadley KA, et al. Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma. *Nature genetics* 2015;47(10):1168–78 doi 10.1038/ng.3398. [PubMed: 26343385]
52. Shiga K, Hara M, Nagasaki T, Sato T, Takahashi H, Takeyama H. Cancer-Associated Fibroblasts: Their Characteristics and Their Roles in Tumor Growth. *Cancers (Basel)* 2015;7(4):2443–58 doi 10.3390/cancers7040902. [PubMed: 26690480]
53. Xu C, Zhao H, Chen H, Yao Q. CXCR4 in breast cancer: oncogenic role and therapeutic targeting. *Drug Des Devel Ther* 2015;9:4953–64 doi 10.2147/DDDT.S84932.
54. Jiang YM, Li G, Sun BC, Zhao XL, Zhou ZK. Study on the relationship between CXCR4 expression and perineural invasion in pancreatic cancer. *Asian Pac J Cancer Prev* 2014;15(12):4893–6. [PubMed: 24998559]
55. Tsai MF, Chang TH, Wu SG, Yang HY, Hsu YC, Yang PC, et al. EGFR-L858R mutant enhances lung adenocarcinoma cell invasive ability and promotes malignant pleural effusion formation through activation of the CXCL12-CXCR4 pathway. *Sci Rep* 2015;5:13574 doi 10.1038/srep13574. [PubMed: 26338423]
56. Mitchell B, Mahalingam M. The CXCR4/CXCL12 axis in cutaneous malignancies with an emphasis on melanoma. *Histol Histopathol* 2014;29(12):1539–46 doi 10.14670/HH-29.1539. [PubMed: 24879309]
57. Zhang J, Liu C, Mo X, Shi H, Li S. Mechanisms by which CXCR4/CXCL12 cause metastatic behavior in pancreatic cancer. *Oncol Lett* 2018;15(2):1771–6 doi 10.3892/ol.2017.7512. [PubMed: 29434873]
58. Cui K, Zhao W, Wang C, Wang A, Zhang B, Zhou W, et al. The CXCR4-CXCL12 pathway facilitates the progression of pancreatic cancer via induction of angiogenesis and lymphangiogenesis. *J Surg Res* 2011;171(1):143–50 doi 10.1016/j.jss.2010.03.001. [PubMed: 20462600]
59. Sleightholm RL, Neilsen BK, Li J, Steele MM, Singh RK, Hollingsworth MA, et al. Emerging roles of the CXCL12/CXCR4 axis in pancreatic cancer progression and therapy. *Pharmacol Ther* 2017;179:158–70 doi 10.1016/j.pharmthera.2017.05.012. [PubMed: 28549596]
60. Feig C, Jones JO, Kraman M, Wells RJ, Deonarine A, Chan DS, et al. Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. *Proc Natl Acad Sci U S A* 2013;110(50):20212–7 doi 10.1073/pnas.1320318110. [PubMed: 24277834]
61. Elham Azizi AJC, Plitas George, Cornish Andrew E., Konopacki Catherine, Prabhakaran Sandhya, Nainys Juozas, Wu Kenmin, Kiseliovas Vaidotas, Setty Manu, Choi Kristy, Dao Phuong, Mazutis Linas, Rudensky Alexander Y., Dana Pe'erdams DJ Single-Cell Immune Map of Breast Carcinoma Reveals Diverse Phenotypic States Driven by the Tumor Microenvironment. doi 10.1101/221994.
62. Gabrilovich DI. Myeloid-Derived Suppressor Cells. *Cancer Immunol Res* 2017;5(1):3–8 doi 10.1158/2326-6066.CIR-16-0297. [PubMed: 28052991]
63. Gentles AJ, Newman AM, Liu CL, Bratman SV, Feng W, Kim D, et al. The prognostic landscape of genes and infiltrating immune cells across human cancers. *Nat Med* 2015;21(8):938–45 doi 10.1038/nm.3909. [PubMed: 26193342]
64. Kumar V, Donthireddy L, Marvel D, Condamine T, Wang F, Lavilla-Alonso S, et al. Cancer-Associated Fibroblasts Neutralize the Anti-tumor Effect of CSF1 Receptor Blockade by Inducing PMN-MDSC Infiltration of Tumors. *Cancer Cell* 2017;32(5):654–68 e5 doi 10.1016/j.ccell.2017.10.005. [PubMed: 29136508]
65. Barua S, Solis L, Parra ER, Uraoka N, Jiang M, Wang H, et al. A Functional Spatial Analysis Platform for Discovery of Immunological Interactions Predictive of Low-Grade to High-Grade Transition of Pancreatic Intraductal Papillary Mucinous Neoplasms. *Cancer Inform* 2018;17:1176935118782880 doi 10.1177/1176935118782880. [PubMed: 30013304]
66. Zhang Y, Velez-Delgado A, Mathew E, Li D, Mendez FM, Flannagan K, et al. Myeloid cells are required for PD-1/PD-L1 checkpoint activation and the establishment of an immunosuppressive environment in pancreatic cancer. *Gut* 2017;66(1):124–36 doi 10.1136/gutjnl-2016-312078. [PubMed: 27402485]

67. Kiss M, Van Gassen S, Movahedi K, Saeys Y, Laoui D. Myeloid cell heterogeneity in cancer: not a single cell alike. *Cell Immunol* 2018 doi 10.1016/j.cellimm.2018.02.008.
68. Ziegenhain C, Vieth B, Parekh S, Reinius B, Guillaumet-Adkins A, Smets M, et al. Comparative Analysis of Single-Cell RNA Sequencing Methods. *Mol Cell* 2017;65(4):631–43 e4 doi 10.1016/j.molcel.2017.01.023. [PubMed: 28212749]
69. Svensson V, Natarajan KN, Ly LH, Miragaia RJ, Labalette C, Macaulay IC, et al. Power analysis of single-cell RNA-sequencing experiments. *Nat Methods* 2017;14(4):381–7 doi 10.1038/nmeth.4220. [PubMed: 28263961]
70. Picelli S, Bjorklund AK, Faridani OR, Sagasser S, Winberg G, Sandberg R. Smart-seq2 for sensitive full-length transcriptome profiling in single cells. *Nat Methods* 2013;10(11):1096–8 doi 10.1038/nmeth.2639. [PubMed: 24056875]
71. Lacar B, Linker SB, Jaeger BN, Krishnaswami SR, Barron JJ, Kelder MJE, et al. Nuclear RNA-seq of single neurons reveals molecular signatures of activation. *Nat Commun* 2016;7:11022 doi 10.1038/ncomms11022. [PubMed: 27090946]




### Significance

Previous studies on pancreatic cancer precursor lesions have identified commonly mutated oncogenes and tumor suppressors (e.g. *KRAS*, *GNAS*, and *TP53*). On the other hand, little is known about the transcriptomic heterogeneity within both cancer and stromal cells that contribute to invasive disease, particularly at the level of single cells. As efforts towards a pre-cancer atlas of epithelial cancers develop, the ability to perform high resolution tumor profiling through single cell transcriptomic studies such as these will allow us to better understand the molecular underpinnings contributing to preneoplastic progression. This is especially relevant for discovery of clinically relevant biomarkers of early stage disease, as well as potential targets for cancer interception.




**Figure 1:** tSNE plots of all 3,343 cells from six lesions included in this study, **(A)** annotated by different tissue samples **(B)** annotated by unique cell types characterized by gene expression (Ductal Epithelium = Ep). **(C)** Feature plots demonstrating expression of specified genes among clusters on the tSNE. **(D)** Clustered heatmap of cell cycle characteristic coefficients per cell within the subpopulations indicated by the header demonstrating a greater proliferative state of PDAC derived cells.



**Figure 2:**

(A) Violin plots of gene expression across lesions types confirm expression of characteristic PDAC and cystic preneoplasia related markers. (B) Heatmap of the top 20 differentially expressed genes used to identify cell phenotypes across each of the ten discrete clusters indicated by the header. (C) Sankey diagram demonstrating epithelial cells profiled from LGD-IPMNs, HGD-IPMNS, and PDAC tissue and where they reside within annotated tSNE clusters (D) Correlation heatmap of Pearson correlation coefficients of hierarchically clustered individual cells across all lesions, identified by originating lesion type and tSNE cluster.





**Figure 4:** Schematic representation of evolving molecular and phenotypic signatures during preneoplastic progression of pancreatic cancer.